Ultrahuman, a leader in digital health technology, and Click Therapeutics, a pioneer in software-based therapeutics, today announced a strategic partnership to launch the world’s first biomarker-driven migraine management tool leveraging FDA-authorized technology. The collaboration aims to combine Ultrahuman’s advanced health monitoring platform with Click Therapeutics’ expertise in digital therapeutics to deliver personalized insights and management strategies for individuals living with migraines.

The innovative tool integrates real-world data and biomarkers to enable tailored intervention planning and symptom tracking. By combining physiological, metabolic, and user-reported behavioral data, the platform is designed to help users identify migraine triggers, predict episode patterns, and support targeted preventive strategies.

Under the partnership, Ultrahuman will incorporate Click Therapeutics’ FDA-authorized digital therapeutic components into its platform, enhancing migraine care through continuous monitoring and individualized recommendations. Click Therapeutics’ experience in developing software as a medical device (SaMD) for neurological conditions ensures that the tool meets clinical and regulatory standards.

The solution’s analytic engine, built on FDA-authorized foundational technology, validates biomarker correlations with migraine patterns and provides evidence-based guidance for users. Ultrahuman’s platform captures real-time physiological and metabolic signals, offering a robust ecosystem for personalized migraine insights. Clinical validation and deployment plans will focus on ensuring usability and effectiveness across diverse migraine populations.

“Advancing migraine care through digital biomarker integration represents a major step toward personalized neurological health management,” said a company spokesperson. “This collaboration has the potential to improve preventive care and reduce the burden of episodic migraine for individuals and healthcare systems alike.”